Free tool
FAERS Monitor: Epsolay
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214510 or its brand name (Epsolay, Benzoyl Peroxide). Reports on generic versions are filed under their own applications.
Reports
1,390
Serious
830
60% of reports
Hospitalization
282
Death reported
49
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective147
- rash94
- erythema83
- pruritus77
- off label use72
- fatigue65
- pain65
- nausea64
- acne60
- anxiety60
- depression54
- dry skin46
- product use in unapproved indication46
- headache45
- diarrhoea44
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 4 |
| 2006 | 7 |
| 2007 | 6 |
| 2008 | 11 |
| 2009 | 11 |
| 2010 | 18 |
| 2011 | 23 |
| 2012 | 28 |
| 2013 | 32 |
| 2014 | 32 |
| 2015 | 47 |
| 2016 | 64 |
| 2017 | 63 |
| 2018 | 77 |
| 2019 | 105 |
| 2020 | 114 |
| 2021 | 95 |
| 2022 | 108 |
| 2023 | 175 |
| 2024 | 138 |
| 2025 | 126 |
| 2026 | 99 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,769 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acneSignal | 60 | 12.0 | 9.4 | 595 |
| erythemaSignal | 83 | 6.1 | 5.0 | 353 |
| dry skinSignal | 46 | 5.2 | 3.9 | 153 |
| depressionSignal | 54 | 3.6 | 2.8 | 99 |
| rashSignal | 94 | 3.3 | 2.7 | 148 |
| anxietySignal | 60 | 3.2 | 2.5 | 89 |
| pruritusSignal | 77 | 3.0 | 2.4 | 105 |
| product use in unapproved indicationSignal | 46 | 2.8 | 2.1 | 52 |
| drug ineffective | 147 | 1.7 | 1.4 | 43 |
| pain | 65 | 1.6 | 1.3 | 15 |
| fatigue | 65 | 1.3 | 1.0 | 3 |
| off label use | 72 | 1.2 | 1.0 | 3 |
| nausea | 64 | 1.2 | 1.0 | 2 |
| headache | 45 | 1.1 | 0.8 | 0 |
| diarrhoea | 44 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.